Search - tctmd.com

Displaying 1 - 20 of 164

Sort: Relevancy | Date

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

Caitlin E. Cox

October 27, 2025

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

Patient-Reported Outcomes are a True Measure of TTVI Value

Presenter: John Spertus

October 30, 2024

Presentation TCT 2024

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Presenter: Ori Ben-Yehuda

October 30, 2024

Presentation TCT 2024

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

Presenter: Mahesh Madhavan

October 30, 2024

Presentation TCT 2024

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Presenter: Susheel Kodali

October 30, 2024

Presentation TCT 2024

Real World TTVI Registries vs. Randomized Trials: Are the Outcomes Aligned?

Presenter: Brian Whisenant

October 30, 2024

Presentation TCT 2024

Transcatheter Tricuspid Valve Replacement - Lessons Learned From TRISCEND II

Presenter: Charles Davidson

October 30, 2024

Presentation TCT 2024

Transcatheter Tricuspid Edge-To-Edge-Repair – Updates from TRILUMINATE and TRI-FR

Presenter: Paul Sorajja

October 30, 2024

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Presentation TCT 2024

Lessons Learned From Recent Clinical Trials (EARLY TAVR and AVATAR)

Presenter: Allan Schwartz

October 30, 2024

Presentation TCT 2024

A Critical Review of Clinical Results in Current TMVR Trials: Implications for Patient Selection and Study Design

Presenter: Firas Zahr

October 30, 2024

Presentation TCT 2024

Transcatheter Repair Versus Surgery in Atrial Mitral Regurgitation: Results From the MATTERHORN Trial

Presenter: Stephan Baldus

October 30, 2024

Advertisement

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

What’s Going to Be Hot at TCT 2025

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Patient-Reported Outcomes are a True Measure of TTVI Value

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Real World TTVI Registries vs. Randomized Trials: Are the Outcomes Aligned?

Transcatheter Tricuspid Valve Replacement - Lessons Learned From TRISCEND II

Transcatheter Tricuspid Edge-To-Edge-Repair – Updates from TRILUMINATE and TRI-FR

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Lessons Learned From Recent Clinical Trials (EARLY TAVR and AVATAR)

A Critical Review of Clinical Results in Current TMVR Trials: Implications for Patient Selection and Study Design

Transcatheter Repair Versus Surgery in Atrial Mitral Regurgitation: Results From the MATTERHORN Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content